Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis

Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo

Brenntag Specialties unveils pharmaceutical and nutraceutical innovations at Vitafoods India

The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being

Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS

The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS

Briefs: Cipla and IOL Chemicals and Pharmaceuticals

Mesalazine is used to treat inflammatory bowel disease

Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets

The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru

Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Alembic receives FDA final approval for Betamethasone Valerate Foam, 0.12%